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Chronic hepatitis in end-stage renal disease: Comparison of HBsAg-
negative and HBsAG-positive patients. To determine the outcome of
chronic hepatitis in ESRD we studied all 358 renal transplant recipients
and 295 hemodialysis patients treated for > 1 year since 1970. The
incidence of chronic hepatitis (elevated SGOT for> 1 year) was 15% (N
= 54) in transplanted and 3.4% (N = 10) in dialysis patients. Forty-eight
percent (26) of transplanted and 50% (5) of dialysis patients were
HB5Ag positive. In the transplanted group, the clinical outcome of
chronic hepatitis was significantly better in HB5Ag-negative compared
to HBsAg-positive patients; 11% died, none from liver disease, and 32%
remitted after a mean follow-up from start of liver disease of 77.3 8.2
months, whereas in the HB5Ag-positive group 54% (14) died, nine from
liver disease, and one remitted after a follow-up of 90.2 8.9months.
Adverse prognostic factors (age, duration of diabetes, and heart dis-
ease) present before ESRD treatment began were similar in both
groups, as was duration of follow-up. Only 14% (2/14) of HBsAg-
negative patients progressed to chronic active hepatitis on liver biopsy
compared to 71% (15/21) of HBsAg-positive patients. Histological
stability in those with serial biopsies occurred in 66% (4/6) of HBsAg-
negative patients, but in only 18% (13/16) of HBsAg-positive patients
with a similar duration of follow-up. No dialysis patients died from liver
disease. We conclude that chronic hepatitis occurs more frequently in
transplanted than dialyzed patients, and that HBsAg-negative chronic
hepatitis has a more benign, clinical, and histological outcome than
chronic HB5Ag-positive hepatitis in renal transplant recipients.
Hépatite chronique au cours de l'insuffisance rénale terminale:
comparaison des patients AgHB5 negatifs et AgHBs positifs. Pour
determiner l'Cvolution de l'hepatite chronique au cours de l'IRC
terminale nous avons Ctudié l'ensemble des 358 transplantés et 295
hémodialysés traités depuis plus d'un an a partir de 1970. L'incidence
de l'hCpatite chronique (SOOT élevées depuis plus d'un an) a etC de
15% (N = 54) chez les transplantes et de 3,4% (N = 10) chez les
dialyses. 48% (26) des transplantCs et 50% (5) des dialyses Ctaient
AgHBs positifs. Dans le groupe transplantes, l'évolution de l'hepatite
chronique a etC significativement meilleure chez les patients AgHBs
nCgatifs que chez ceux AgHBs positifs: 11% sont dCcCdCs, aucuns de
maladie hCpatique, et 32% ont guCri après une durCe moyenne de
surveillance de 77,3 8,2 mois après le debut de Ia maladie hépatique.
Dans le groupe AgHBs positifs, 54% (14) sont dCcCdCs, 9 de leur
maladie hepatique, et un a gueri apres un suivi de 90,2 8,9 mois. Les
facteurs de mauvais pronostic (age, durCe du diabète et maladie
cardiaque) presents avant Ic traitement de l'insuffisance rCnale
chronique dtaient identiques dans les deux groupes, de méme que Ia
durée de Ia surveillance. 14% (2/14) seulement parmi les patients
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AgHBs nCgatifs ont progresse vers une hepatite chronique active sur la
biopsie hepatique, contre 71% (15/21) chez les patients AgHBs positifs.
Chez les malades ayant eu des biopsies rCpCtCes, une stabilité
histologique a etC observCe chez 66% (4/6) des patients AgHB5 nCgatifs,
mais seulement chez 18% (13/16) des patients AgHB5 positifs, avec une
durCe de surveillance identique. Aucun patient dialysC n'est mort de
maladie hCpatique. Nous concluons que I'hCpatite chronique survient
plus frequemment chez les patients transplantCs que dialyses, et que
l'hCpatite chronique sans AgHB5 a un devenir cinique et histologique
meilleur que celui de l'hepatite chronique avec AgHBs chez les patients
transpiantCs.
Over the last ten years, data has accumulated to suggest that
chronic liver disease in renal transplant recipients is responsible
for considerable morbidity and mortality [1—101. The incidence
of chronic hepatitis in renal transplant patients has been esti-
mated to be 6 to 16% [1—3] and is usually due to either hepatitis
B virus (HBV) infection or non-A, non-B disease. Recent
prospective histological studies demonstrated that in the immu-
nosuppressed renal transplant patient, HBV infection often
resulted in the development of chronic active hepatitis, which
may lead to cirrhosis and death from hepatoma and hepatic
failure [11—13]. The natural course of HBV disease in renal
transplant recipients may be progressive and distinct from that
in dialysis patients [12, 13].
Non-A, non-B hepatitis is now the most frequent cause of
transfusion-related hepatitis [14]. It has a propensity to chro-
nicity in patients without renal disease [15—17]. Among trans-
plant patients, progressive liver disease due to non-A, non-B
hepatitis has been reported to occur in about 50% of cases [3],
although it may be morphologically more benign than in HBV
disease [18]. In patients with long-functioning renal allografts,
hepatic failure was the leading cause of death, often associated
with extrahepatic sepsis [4]. Actual survival of patients with
chronic hepatitis was significantly higher when compared to
those without chronic hepatitis [4]. A recent editorial [10]
emphasized the lack of studies available to establish the impact
of transplantation on the course of chronic HBV liver disease.
Similar studies are lacking in patients with non-B hepatitis and
are necessary because current policy demands that most pa-
tients receive blood transfusions before transplantation. This
policy may increase short-term allograft survival, but at the
expense of long-term patient survival.
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The purposes of the present study were: (1) to ascertain the
incidence and causes of chronic hepatitis in patients treated for
end-stage renal disease (ESRD) in two hospitals in Montreal,
the Royal Victoria Hospital and Maisonneuve-Rosemont Hos-
pital, since routine HBsAg testing became available; (2) to
determine the clinical and histological progression of chronic
hepatitis in patients treated for ESRD; (3) to study the cause of
death in ESRD patients with chronic hepatitis; and (4) to assess
whether the outcome of chronic hepatitis was different in
patients who were HBsAg negative compared to those who
were HBsAg positive.
Methods
Patients
We studied all patients who were treated for ESRD for longer
than 1 year and who received their first definitive treatment for
chronic renal failure (dialysis or kidney transplant) at the Royal
Victoria Hospital and Maisonneuve-Rosemont Hospital from
January, 1970, to June, 1983. During that period, 358 had
transplants that functioned for longer than 1 year and 295
patients were maintained on dialysis for longer than 1 year.
From these groups, we studied every patient who developed
chronic hepatitis, defined as elevated serum glumatic
oxaloacetic transaminase levels for at least 1 year.
Renal transplant group
Between 1970 and 1983, 54 of 358 patients who had a
functioning renal allograft for at least 1 year developed chronic
hepatitis. This group consisted of 38 male patients and 16
female patients whose mean age was 36.4 1.4 SE years. All
underwent hemodialysis prior to transplantation. The mean
duration of dialysis was 13.2 1.4 months (range 1 to 84
months). All patients but one were treated with a conventional
immunosuppressive regimen consisting of high-dose prednisone
immediately following transplantation, tapering to a mainte-
nance dose of 15 mg/day 1 year after transplantation.
Azathioprine maintenance dose was usually 100 to 125 mg/day.
Patients who developed evidence of acute rejection during
follow-up were usually treated intravenously with methyl pred-
nisone (750 mg) or high oral prednisone cyclophosphamide(400 mg). One patient did not receive azathioprine, but
cyclosporine, according to the Canadian Multicentre Study
Protocol [19]. Azathioprine was stopped in six patients and
reduced below 100 mg/day for more than 1 year in an additional
11 patients. Azathioprine was stopped in one patient because of
a skin epithelioma, in 15 transplant recipients following the
onset of chronic liver disease, in two patients when they
returned to dialysis, and in one patient because of a very good
graft function with low immunosuppression dosage. The under-
lying renal diseases were: primary glomerulonephritis (N = 30),
secondary glomerulonephritis (N = 2), obstruction/chronic
pyelonephritis (N = 7), diabetes mellitus (N = 4), polycystic
kidney disease (N = 3), medullary cystic disease (N = 1),
congenital hypoplasialsolitary kidney (N = 2), cystinosis (N =
1), malignant hypertension (N = 2), gout (N = 1) and analgesic
nephropathy (N 1).
Chronic hemodialysis group
Ten of 295 patients with ESRD treated by dialysis for more
than 1 year developed chronic hepatitis. This group consisted of
six male and four female patients whose mean age was 39 years
4 SE. Two patients had undergone one renal transplant during
the period of follow-up and one patient received two trans-
plants, all of which failed within 3 months. While on dialysis,
none of these patients received immunosuppressive agents. The
underlying renal diseases were: chronic glomerulonephritis (N
= 5), tuberculosis (N = 1), chronic pyelonephritis/reflux
nephropathy (N = 2) and interstitial nephritis (N = 2).
Clinical data
The records of all 64 patients treated for ESRD in both study
groups were reviewed to document clinical signs and problems
related to chronic liver disease. Each living patient was evalu-
ated at his or her last follow-up visit for the presence of
jaundice, encephalopathy, flapping tremor, abnormal liver size,
splenomegaly, and ascites. Age, presence of diabetes mellitus,
occurrence of congestive heart failure, or myocardial infarction
before treatment for ESRD began and other serious co-morbid
illnesses which might have an adverse effect on long-term
prognosis were recorded. The cause of death was assessed by
the primary physician.
Immunosuppressant dosage (azathioprine, steroids, cyclo-
sporine) were recorded every 6 months from time of entry in the
study to last follow-up. Exposure to liver toxins, alcohol use,
and drug schedules were reviewed in all patients. Three trans-
plant patients were assessed by their personal physicians as
alcohol abusers (daily alcohol intake > 6 glasses beer/spirits per
day). Hepatotoxicity caused by drugs was excluded in all
patients, although one transplant recipient received cyclospo-
rime A and a second one isoniazid.
Laboratory data
Serum glumatic oxaloacetic transaminase (SGOT) and serum
glumatic pyruvic transaminase (SGPT), alkaline phosphatase,
total bilirubin, and HBsAg were recorded before treatment for
ESRD began and then every 6 months during time of follow-up.
SGOT were recorded monthly (if performed) for the year prior
to the last liver biopsy. When no biopsy was available (because
patients had remitted, were dead, or refused the biopsy)
monthly SGOT were recorded for the year prior to last fol-
low-up or death.
SGOT, SGPT, and alkaline phosphatase were measured by
autoanalyzer. HBsAg was detected by radioimmunoassay, but
the sensitivity for HBsAg detection improved over the 14 years
of the study.
Definitions
Chronic hepatitis was defined as a mean SGOT or SGPT level
greater than 40 units/liter for at least 1 year and still elevated 1
year after first high level was observed. We chose this SGOT
level because many transplant patients with chronic HBV liver
disease have aggressive liver disease with SGOT levels less
than twice normal [12] and because SGOT activity is often
decreased in azotemic patients [20, 21].
Hepatitis B liver disease denoted the presence of circulating
HBsAg.
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Non-B liver disease was defined as the presence of elevated
enzymes level (> 40 .dliter) for at least 1 year in the absence of
circulating HBsAg or the development of infiltrative disease
diagnosed on liver biopsy or observed in another organ, or
other known hepatotoxic agents.
Remission was indicated when liver enzymes were normal for
at least 1 year following hepatitis.
Histological assessment of liver biopsy specimens
Patients who were alive at time of the study (1983—4) and in
whom transaminase levels had been raised for the previous 12
months (mean SGOT > 40 dliter) underwent liver biopsies.
Previous liver biopsy or autopsy specimens were obtained.
Sixteen of the 54 patients with chronic hepatitis had partici-
pated in a prospective histological study of HBsAg-positive
liver disease in renal transplant recipients which we have
reported previously [12, 131. All biopsy specimens were embed-
ded in parafin, sectioned, and stained with hematoxylin and
eosin, periodic acid Schiff, Masson trichrome, and Perl's prus-
sian blue. Both the degree of inflammatory cell infiltration and
fibrosis in the liver were graded blind to the clinical state on a
scale of 1 to 3. This system was applied separately to each
perivenular, lobular, portal, periportal, and septal area on the
biopsy. The total inflammatory and total fibrosis scores per
biopsy were then calculated [12, 221. Based on these and the
overall morphological appearance, a histological diagnosis was
made according to one of eight distinct entities as follows: (1)
normal; (2) virus only (V): histologic evidence of HBV within
hepatocytes, "ground glass" cells, in otherwise normal biopsy;
(3) reactive hepatitis (H): hepatocyte necrosis with
reticuloendothelial proliferation, sometimes with leucocytic
and histiocytic infiltration; (4) chronic persistent hepatitis
(CPH): significant portal mononuclear cell infiltration, absent or
minimal piecemeal necrosis, insignificant fibrosis, and retention
of normal lobular architecture; (5) chronic active hepatitis
(CAH): portal and periportal inflammation with piecemeal
necrosis, varying degrees of lobular hepatitis and portal fi-
brosis, often with lobular extention and bridging; (6) cirrhosis
(C) with diffuse hepatic fibrosis and nodular regeneration; (7)
hepatocellular carcinoma or hepatoma (K); and (8) other
abnormalities.
In the results, categories 2 to 4 (V, H, and CPH) are called
Group I (non-aggressive liver disease) and categories 5 to 7
(CAH, C, and K) are called Group II (aggressive liver disease).
Ninety-two biopsy specimens were assessed, obtained from
34 of the 64 patients. In the transplant groups 22 of the 54
patients had serial biopsies (the number varying from 2 to 7) and
an additional ten patients had one biopsy. Liver biopsy speci-
mens were not available in 22 patients because they were dead
(N = 2), liver disease had remitted (N = 8), they refused biopsy(N = 11) or had a medical contraindication (N = 1).
In the chronic hemodialysis group, three biopsy specimens
were available in two patients. One patient had one liver biopsy
within the first 16 months of starting treatment and the second
was carried out after clinical manifestations of chronic liver
disease had occurred. One other hemodialysis patient under-
went one liver biopsy. In the remaining patients, no biopsy was
available because three of them had biological remission, two
were dead without autopsy and three were alive but refused
biopsy.
Table 1. Demography of HBsAg-positive and negative renal
transplant recipients with chronic hepatitis
HBsAg-
positive
HBsAg-
negative Total
Sex, FIM
Mean age at time of
transplant, years
Time on dialysis before
transplantation, months
Time of follow-up after
transplantation, months
Time of follow-up after
chronic liver disease
developed, months
Number of patients
8/18
34.7 2.1k
10.4 3.1
103.8 9.2
90.2 8.9
26
8/20
37.6 1.9
15.7 3.0
95.2 9.5
77.3 8.2
28
16/38
36.4 1.4
13.2 1.4
98.1 6.3
83.5 6.0
54
a Standard error
Results
Incidence and causes of chronic hepatitis in ESRD
Incidence: Sixty-four patients had elevated liver enzymes for
at least 1 year. The incidence of chronic hepatitis in the renal
transplant recipients treated for at least 1 year was 15%
(54/358). In the hemodialysis patients treated for more than one
year, it was 3.4% (10/295), which was significantly lower than in
the transplant group (x 2 = 25.2, P < 0.005). The incidence of
chronic hepatitis has decreased in renal transplant recipients
during recent years, the incidence being 20% from 1970—1975,
12% from 1975—1980, and 10% from 1980—1983.
Causes: The etiology of chronic hepatitis in patients treated
for ESRD was divided into two categories according to the
results of HBsAg screening. Forty-eight percent (26/54) of renal
transplant recipients with chronic hepatitis were HBsAg posi-
tive, as were 50% (5/10) of hemodialysis patients. Demographic
data for HBsAg-positive and negative renal transplant recipi-
ents with chronic hepatitis is shown in Table 1.
HBsAg-positive transplant patients with chronic hepatitis
Figure 1 illustrates the time at which chronic hepatitis was
initially detected (using liver enzyme determination), the dura-
tion of chronic hepatitis during time of follow-up, the time post
transplant at which HBsAg was first detected, the duration of
the chronic carrier state, and the results of liver biopsies.
Hepatitis B serology. Seven patients were HBsAg positive
prior to transplantation, four were found to be positive at time
of transplant, ten within six months post transplantation, and
five more than 6 months after transplantation (Fig. 1). All of
these patients had serial HBsAg tests during time of follow-up
and none of the 26 converted to negative.
The duration of HBsAg-carner state before hepatitis ap-
peared varied between 0 and 208 months. Four patients had
HBsAg first detected after liver enzymes rose (range, 29 to 74
months after enzyme elevation). The other 22 patients who
were found to be HBsAg positive before or at time of enzyme
elevation had a mean chronic carrier state of 25.0 9.7 months.
Clinical sequelae. Fourteen of the 26 patients died, nine of
whom (64%) died from liver disease (Table 2). Among the nine
patients who died with liver disease, one had chronic persistent
hepatitis, two chronic active hepatitis, five cirrhosis, and one
hepatoma. The mean duration of chronic hepatitis was 84.5
13.7 months (21 to 161 months).
Clinical signs of chronic liver disease were not observed in
patients within the group with benign histology (Group I). One
patient with chronic persistent hepatitis died from sepsis and
hepatic failure. However, autopsy revealed acute hepatitis with
underlying chronic persistent hepatitis.
Biochemical remission occurred in one of the 26 patients
while transplanted. Two patients went back to dialysis having
had a functioning transplant for more than 1 year. One patient
had already progressed to cirrhosis and eventually died from
Table 2. Causes of death in HBsAg-positive and negative transplant
patients with chronic hepatitis
HBsAg-positive
Group I. End-stage liver disease
hepatic failure
sepsis + hepatic failure
gastrointestinal hemorrhage
hepatoma
bronchopleural fistula + ascites
Group II. Other causes
sepsis
brain sarcoma
cardiac disease
HBsAg-negative
pneumonia
metastatic cancer
myocardial infarction
liver disease. The second patient remitted and did not undergo
biopsy.
Morphological outcome. Nineteen patients had histological
assessment at most recent follow-up, 14 of whom had devel-
oped chronic active hepatitis or cirrhosis (Group II histology).
Morphological progression. Histological deterioration was
defined as greater than one grade change in total fibrosis score,
and it was observed in 12 of 16 (75%) patients who had serial
biopsies. A change from Group I benign histology to Group II
aggressive histology occurred in ten of the 15 patients (67%).
Eight of the 12 patients who progressed died from liver disease.
Only one patient out of 16 had histological improvement after 72
months of follow-up, regressing from CPH to virus only. No
t LID patients ever regressed from Group II to Group I. The mean
LID follow-up from start of chronic liver disease to last biopsy was
C 69.7 29.4 months for the four-patients who remained stable
and 87.4 12.8 for the 12 who had histological deterioration.
156 Risk of cirrhosis and hepatic failure. Twenty-one patients
free from cirrhosis at the time they were found to be HBsAg
positive were followed for a total of 159 years (mean/patient,
7.57 years). Eight of the 21 subsequently developed cirrhosis,
making the risk of developing cirrhosis 5.0% per patient year.
The risk of developing aggressive liver disease (Group II) was
9.4% per patient year. Fifteen of 21 patients developed chronic
active hepatitis or cirrhosis after a mean follow-up of 7.57
years.
The risk of death from liver disease was 4.1% per patient
year, specifically, 9 of 26 patients died from liver disease after
a mean follow-up of 8.3 years.
Assessment of adverse prognostic factors which were present
before treatment for ESRD began revealed that nine of the 26
patients had an episode of congestive heart failure before
starting treatment for ESRD, one had had a myocardial infarct
and three had diabetes mellitus.
HBsAg-negative transplant recipients with chronic hepatitis
Figure 2 shows the duration of follow-up, evolution of chron-
ic hepatitis, results of liver biopsies, and clinical outcome in all
HBsAg-negative transplant patients with chronic hepatitis.
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Fig. 1. Clinical, biochemical, and histological evolution of HBsAg-
positive chronic hepatitis in renal transplant recipients. Symbols are:
f , time of detection of HBsAg; •, patient refused biopsy; tLD, death
from liver disease; t, death from other causes; _r1_, SGOT > 40
Jliter; —, time on transplant, ---, back to dialysis, — - —,lost from
follow-up; N, normal liver; V, virus only; H, reactive hepatitis; P,
chronic persistent hepatitis; F, fibrosis only; A, chronic active hepatitis;
C, cirrhosis; K, hepatoma; ®, remission: SGOT normal for> 1 year.
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Clinical sequelae. Three of 28 patients died, none of them
from hepatic failure (Table 2). One of the three patients had
remission of chronic hepatitis before dying, one had persistent
elevated enzymes but no autopsy was obtained, one died in
another city and no histological data was available. None of
them had any clinical signs of liver disease. Among the 25 living
patients with chronic hepatitis, eight had remitted at last
follow-up. Thus, remission from chronic hepatitis had occurred
in 32% of patients with chronic non-B hepatitis. The 17 remain-
ing transplanted patients with persistent HBsAg-negative
chronic hepatitis have been followed for 65 8.7 months since
start of liver disease, one of whom has developed splenomegaly
and osephageal varicies when followed for 96 months. One
patient went back to hemodialysis and remitted after 36 months
on dialysis.
Morphological outcome. At least one liver biopsy was per-
Outcome
HBsAg-
positive
HBsAg-
negative P
Remission (biochemical) 1/26 9/28 6.6 < 0.05
Died 14/26 3/28 8.3 < 0.05
Died from liver disease 9/26 0/28 11.6 < 0.005
Resulted in chronic active
hepatitis or cirrhosis on
biopsy 15/21 2/14 10.6 < 0.005
Remained histologically
stable on serial biopsies 3/16 4/6 — —
formed in 14 of the 28 patients. Six of the 14 patients showed
normal liver biopsy, having had chronic hepatitis for 53.3 24
months. One patient had non-specific reactive hepatitis after
123 months of chronic hepatitis. Five patients developed
chronic persistent hepatitis after a mean duration of hepatitis
before last biopsy of 31.8 6.6 months, and two developed
CAH after a mean duration of chronic hepatitis of 46.5 10.5
months. Only six patients had serial biopsies. None of the six
patients evolved from Group I to Group II after a mean
follow-up of 72.5 months (± 20.7), following start of liver
disease. Only one patient had an increase in fibrosis score of
greater than 1.
Risk of cirrhosis and hepatic failure. The risk of dying from
hepatic failure was zero after a mean follow-up from start of
chronic hepatitis of 76.6 months. The risk of developing end-
stage liver disease was 0.6. One of the 28 patients developed
portal hypertension after a mean follow-up from start of chronic
hepatitis of 6.3 years. Two of the 14 patients who had at least
one biopsy developed CAH during a mean follow-up from start
of chronic hepatitis of 5 years. The risk of developing aggres-
sive disease (Group II) was 3.5% per patient year following start
of liver disease.
Seven of the 28 patients had congestive heart failure before
treatment for ESRD began, none had had myocardial
infarction, and one had diabetes mellitus.
Comparison of chronic hepatitis sequelae in HBsAg-positive
and negative transplanted patients (Table 3)
Clinical sequelae. The overall mortality rate in transplant
patients with chronic hepatitis was significantly higher in the
HBsAg-positive patients (54%), compared to HBsAg-negative
transplant recipients (11%).
No HBsAg-negative transplant patients died from liver dis-
ease and 32% underwent spontaneous remission, compared to
35% mortality rate from liver failure in HBsAg-positive patients
and 4% remission during period of transplantation. The time of
follow-up after chronic hepatitis started was similar for both
groups, being 90.2 8.9 months in the HBsAg-positive group
and 77.3 8.2 in the HBsAg-negative group. Adverse prognos-
tic factors present before treatment for ESRD were similar in
HBsAg-positive and HBsAg-negative patients. The mean age at
time of transplant in the former group was 35 2 and in the
latter group it was 38 2 years. There was no significant
difference between the two groups comparing the incidence of
congestive heart failure, myocardial infarction, and diabetes
mellitus before treatment for ESRD began.
Table 3. Comparison of the clinical and histological sequelae in
HB5Ag-positive and negative renal transplant recipients
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Fig. 2. Clinical, biochemical, and histological evolution of HB5Ag-
negative chronic hepatitis in renal transplant recipients, Symbols
shown in Fig. 1.
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Morphological sequelae. Only two of the 14 HBsAg-negative
patients who had liver biopsies developed chronic active hep-
atitis after a mean duration of hepatitis of 50 months, compared
to 15 of 21 HBsAg-positive patients (x2 = 10.6, P < 0.005). The
histological progression of chronic liver disease when assessed
by serial biopsies appeared less aggressive in patients with
HBsAg-negative hepatitis, compared to the HBsAg-positive
patients. Sixty-six percent of the non-B patients remained
histologically stable (mean follow-up of 60 24 months alter
chronic hepatitis started), compared to only 19% in the HBsAg-
positive group (follow-up 70 29 months after chronic hepatitis
started). There was no statistical difference in both groups
between the mean duration of follow-up after chronic hepatitis
started.
Patients on chronic hemodialysis with chronic hepatitis
Ten patients treated by dialysis for more than 1 year had
chronic hepatitis, half of whom were HBsAg positive.
HBsAg-positive. Three patients were HBsAg positive before
chronic hepatitis started, and two had HBsAg first detected
alter chronic hepatitis started (7 and 17 months after). One out
of five patients reverted to an HBsAg-negative state within 30
months. The four others remained positive during the entire
follow-up period.
Only one patient had serial liver biopsies. He evolved from
virus only to cirrhosis within 92 months. One of the five patients
died from cardiac arrhythmias. No patient has died from
chronic liver disease. One patient has had remission of chronic
hepatitis, and the other three patients have refused biopsy.
HBsAg-negative. Five patients had HBsAg negative chronic
hepatitis. All but one patient (80%) with non-B hepatitis remit-
ted, compared to only one HBsAg-positive patient (20%). One
patient died from sudden death and no patient developed signs
of cirrhosis. The single patient whose chronic hepatitis had not
remitted at time of the study refused biopsy. A single biopsy
was available in one patient and it showed reactive hepatitis.
Discussion
This study demonstrates that in patients with end-stage renal
disease, chronic hepatitis: (1) occurs less frequently in patients
on dialysis compared to transplant patients, (2) has a marked
tendency to morphological progression in HBsAg-positive renal
transplant patients, associated with an increase in mortality rate
due to liver disease, and (3) has a significantly better clinical and
histological outcome in transplant patients with chronic
HBsAg-negative hepatitis compared to those who are HBsAg
positive.
Incidence of chronic hepatitis. The usual definition of chronic
hepatitis used in patients without renal disease is the persis-
tence of a serum glutamate pyruvate transaminase level or
glutamatic oxaloacetic transaminase level greater than twice the
upper limit of laboratory normal for longer than 6 months [23].
However, decreased SGOT activity occurs in dialysis patients
[20, 211. Consequently, SOOT level above the upper limit of the
assay in dialysis patients is probably clinically important and
may represent high levels of liver disease activity. Further-
more, in transplant patients with hepatitis B disease, the
relationship between serum liver enzyme levels and the activity
of liver disease is poor; patients with active inflammation on
liver biopsy often having SOOT levels less than twice normal
[12, 13]. Therefore, we have entered patients in our study who
persistently have had liver enzymes above the upper limit of
normal for at least 1 year.
In our study, the overall incidence of chronic hepatitis among
ESRD patients was 9.8%, but there was a much higher inci-
dence in transplant patients (15%) compared to patients on
dialysis (3.4%). In other studies, the incidence of chronic
hepatitis was estimated to be between 6 and 16% in renal
transplant recipients [1—3] and 5 to 28% in hemodialysis patients
[22, 24, 25]. Since our criteria for entry in the study were
identical in both transplant and dialysis groups, three different
explanations could explain our findings. First, SOOT measure-
ments may have been bad indices of chronic hepatitis in
patients on dialysis and may have led to an underestimation of
viral-induced liver disease in that group of patients because
decreased serum SGOT activity has been reported in the serum
of uremic patients [20, 211. Second, the diminished im-
munoresponsiveness in transplant patients who receive im-
munosuppressive therapy may have put them at increased risk
of reactivation of viral replication [6] and of stimulating his-
tologic progression. It has also been reported that patients with
normal liver function at time of transplant who subsequently
developed active liver disease had abnormal liver biopsies at
time of transplantation [11]. Thus, the infection occurred during
dialysis, but did not progress to give clinical or biological signs
until immunosuppression was prescribed. Immunosuppression
of HBsAg-positive patients without ESRD who had chronic
active hepatitis has also been associated with deleterious effects
[27, 28]. Finally, the data may have resulted from selection bias.
Preferential treatment with transplantation was often given to
HBsAg-positive dialysis patients in the early 1970s. One reason
for this was that it was thought that immunosuppression could
prevent progression of aggressive disease [22]. Another reason
was that dialysis doctors wanted to decrease the risk of cross
infection between HB5Ag-positive and negative patients and,
therefore, advised HBsAg-positive transplant patients to un-
dergo transplantation.
Hepatitis B-positive hepatitis. In our study, HB virus was
responsible for about one-half the cases of chronic hepatitis in
both dialysis and transplant groups. In transplant patients,
considerable controversy remains concerning their respective
evolutions [10, 14]. It appears from prospective histologic
studies that HBV liver disease tends to progress to aggressive
liver disease in renal transplant recipients [11—13]. HBsAg-
positive patients treated with hemodialysis have also been
reported to progress to chronic active hepatitis [29]. However,
detailed review of the literature reveals the lack of long-term
follow-up study in ESRD patients with chronic hepatitis and of
any comparison between the outcome of HBsAg-positive and
negative chronic liver disease in dialysis or in transplant
patients.
In the general population, persistent HBs antigenemia for
more than 6 months occurs in about 10% after acute hepatitis,
one-half of whom remain carriers for longer than 2 years. In
persistent carriers, clinical and histological evidence of chronic
hepatitis may develop [301. However, only a small proportion
develop chronic active hepatitis [31, 32]. Progression of liver
disease is usually insidious in the absence of cirrhosis [33—351.
The natural history of HBY disease in patients without ESRD is
shown in Figure 3A. The outcome in transplanted patients is
markedly different (Fig. 3B). In the current study, none of the
HBsAg-positive transplanted patients with chronic hepatitis
converted to negative and only one of the dialysis patients did
so. A very high proportion (7 1%) of HBsAg-positive renal
transplant recipients progressed to chronic active hepatitis, and
only 18% of those with serial liver biopsies remained histolog-
ically stable. This progression was associated with a high
mortality rate from liver disease. This is consistent with the
report from Belgium of a fivefold increased mortality due to
hepatic failure in HBsAg-positive patients who became infected
in the late 60s and 70s [91 and with our prospective clinical and
histologic studies in HBsAg-positive transplant patients [12, 13].
HBsAg-negative hepatitis. In this study, renal transplant
recipients with HBsAg-negative hepatitis had a much less
aggressive course when compared with HBsAg-positive pa-
tients. Biochemical remission occurred spontaneously in 32%
of HBsAg-negative patients, compared to zero remission in
HBsAg-positive patients, and mortality was significantly less
than that of HBsAg-positive patients. This difference in mor-
tality was not the result of selection bias. Adverse prognostic
factors before treatment for ESRD began, such as age, diabetes
mellitus, and heart disease [36], were similar in both HBsAg-
positive and negative groups.
Although fewer serial biopsy specimens were obtained, the
overall histologic outcome of chronic non-B hepatitis was less
aggressive compared to the HBsAg-positive patients and con-
sistent with the clinical outcome. Only two of the 14 patients
(14%) with liver biopsies developed aggressive disease, and
66% of those with serial biopsies remained histologically stable.
The duration of follow-up from start of chronic hepatitis was
similar to that in the HBsAg-positive chronic hepatitis patients.
Figure 4, upper panel, shows the result of chronic non-A,
non-B hepatitis in patients without end-stage renal failure. In
these patients, the histological outcome of chronic non-A,
A Usual outcomes in HBV infection
Chronic hepatitis in ESRD patients 965
B Outcomes of HBV in transplant recipients
Chronic carrier
normal liver
Fig. 3. A. Usual clinical and histological
outcomes of acute hepatitis B infection in
patients without end-stage renal fialure. (From
[31] and a slide of Dienstag, DL, personal
communication.) B Outcomes in HBV
infection in renal transplant recipients (from
[12, 13] and this study.)
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HB,Ag-negative
chronic hepatitis
in patients without ESRD
(35% of acute hepatitis)
5%
Cirrhosis Death
liver
disease
i/o i/o
CAH Cirrhosis Death
liver
disease
Fig. 4. Clinical and morphological outcomes of chronic non-A, non-B
hepatitis in patients without ESRD (upper panel) (from [31]) and in
renal transplant recipients (lower panel).
study, the rate of biochemical remission was higher in HBsAg-
negative compared to HBsAg-positive patients with chronic
hepatitis, but death from chronic liver disease did not occur in
either group. In view of the frequency of chronic hepatitis in
ESRD patients and in view of the policy to give pretranspiant
blood transfusions to most potential renal transplant recipients,
much larger, multi-center studies to investigate both clinical
and morphological outcomes are required to confirm our find-
ings and to determine the exact long-term risk of both RB sAg-
positive and negative chronic hepatitis in patients with ESRD.
Reprint requests to Dr. P.S. Parfrey, Division of Nephrology, The
Wealth Sciences Centre, St. John's, Newfoundland, Canada
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